Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has announced that Ascent Health, the second largest Payer organisation in the US, will cover Sofdra (sofpironium) topical gel, 12.45 per cent.
Ascent Health represents approximately 65 million people.
Botanix said Sofdra will be covered in line with the target patient access restrictions previously communicated to shareholders.
Sofdra is the first and only new chemical entity approved by the FDA to treat primary axillary hyperhidrosis, which impacts approximately 10 million patients in the US.
The Ascent coverage adds to the existing Payer coverage already completed or actively being finalised by Botanix with Payers, who represent more than 110 million people together. Botanix said reimbursement coverage is progressing as expected.